Black Diamond Therapeutics, Inc. (BDTX)
| Market Cap | 127.21M +18.4% |
| Revenue (ttm) | n/a |
| Net Income | -43.21M |
| EPS | -0.76 |
| Shares Out | 57.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,167,786 |
| Open | 2.305 |
| Previous Close | 2.250 |
| Day's Range | 2.180 - 2.330 |
| 52-Week Range | 1.930 - 4.940 |
| Beta | 3.34 |
| Analysts | Strong Buy |
| Price Target | 9.86 (+344.14%) |
| Earnings Date | May 7, 2026 |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price target is $9.86, which is an increase of 344.14% from the latest price.
News
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigatio...
Black Diamond Therapeutics Transcript: Study result
Phase II results show silevertinib achieved a 60% objective response rate and 86% CNS response rate in frontline EGFR NCM non-small cell lung cancer, with a median PFS of 15.2 months and manageable safety profile. No new brain metastases developed during treatment.
Black Diamond Therapeutics Press release: Study result
Black Diamond Therapeutics issued a press release on May 21, 2026, disclosing material business information to investors.
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
Black Diamond Therapeutics Slides: Corporate presentation
Black Diamond Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase...
Black Diamond Therapeutics Quarterly report: Q1 2026
Black Diamond Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Black Diamond Therapeutics Earnings release: Q1 2026
Black Diamond Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Black Diamond Therapeutics Proxy statement: Proxy filing
Black Diamond Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Black Diamond Therapeutics Proxy statement: Proxy filing
Black Diamond Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $11 from $10 and keeps a Buy rating on the shares. Published first on…
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush
Wedbush raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $14 from $13 and keeps an Outperform rating on the shares following quarterly results and updates regarding silevertinib…
Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)
“We continue to focus on advancing silevertinib for the treatment of patients with EGFRm NSCLC and EGFR altered GBM,” said Mark Velleca, president and CEO of Black Diamond Therapeutics (BDTX).
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Earnings release: Q4 2025
Black Diamond Therapeutics released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Black Diamond Therapeutics Annual report: Q4 2025
Black Diamond Therapeutics has published its Q4 2025 annual report on March 16, 2026.
Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Silevertinib, a fourth-generation EGFR inhibitor, shows strong efficacy and CNS activity in non-classical EGFR NSCLC and is advancing into a pivotal GBM trial. Key PFS data in NSCLC are expected in Q2 2024, with GBM trial enrollment starting soon and results anticipated in 2028.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler
Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from $9 and keeps an Overweight rating on the shares. Following a flurry…
Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Silevertinib’s Phase II data in non-classical EGFR-mutant lung cancer showed a 60% response rate and strong CNS activity, with durability and PFS data expected in Q2 2026. Plans include FDA engagement, a pivotal trial, and a Phase II GBM study, supported by a strong financial runway.
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy without a price target While the headline overall response rate in the silevertinib 1L non-classical EGF...
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics (BDTX) to Neutral from Buy.